BRIEF-Helix Biopharma Q2 loss per share C$0.03

Wed Mar 16, 2016 6:45pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

March 16 (Reuters) - Helix Biopharma Corp :

* Helix Biopharma Corp. announces second quarter fiscal 2016 results

* Cash reserves as at January 31, 2016 insufficient to see current research and development initiatives through to completion

* Management considers securing additional funds, expected to be through issuance of equity securities of company

* Q2 loss per share C$0.03

* Cash reserves as at Jan 31, 2016, are insufficient to meet anticipated cash needs for working capital and capital expenditures through next 12 months Source text for Eikon: Further company coverage: